HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hatch, Harkin Call For Withdrawal of NDI Draft Guidance

This article was originally published in The Tan Sheet

Executive Summary

Sens. Hatch and Harkin ask FDA to craft a new document to replace the current NDI notification draft guidance, recommending the agency “provide needed clarification” on what constitutes an NDI.

You may also be interested in...



McCain-Dorgan NDI Guidance, Steroid Provisions In Senate Food Safety Bill

Requirements that benefit dietary supplement manufacturing and that gained Sen. John McCain's support after he initially proposed legislation considered a threat to the industry are part of the food safety reform bill pending in the Senate.

Coalition Pushes Congress On OTC Purchases With Health Savings Accounts

The Health Choices Coalition sent letters urging House and Senate members to support legislation that would strike the health care reform law requirement that consumers obtain a prescription in order to purchase OTCs with a pre-tax savings account.

TheraBiogen Supports Theramax Expansion With Education Push

Homeopathic firm TheraBiogen plans to roll out products “every six to nine months” to add to its existing lineup of homeopathic remedies for allergy and cold and flu, says CEO Kelly Hickel. The firm also counts on sales growth from a social media campaign to explain what is not in its products as well as what is.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS124670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel